Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Sold by Amalgamated Bank

Amalgamated Bank lessened its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 4.1% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 32,850 shares of the biopharmaceutical company’s stock after selling 1,406 shares during the period. Amalgamated Bank’s holdings in Catalyst Pharmaceuticals were worth $653,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Sei Investments Co. lifted its stake in shares of Catalyst Pharmaceuticals by 64.3% in the 1st quarter. Sei Investments Co. now owns 83,360 shares of the biopharmaceutical company’s stock worth $1,329,000 after acquiring an additional 32,621 shares during the period. Susquehanna Fundamental Investments LLC acquired a new stake in shares of Catalyst Pharmaceuticals in the 2nd quarter worth $258,000. Integral Health Asset Management LLC acquired a new stake in shares of Catalyst Pharmaceuticals in the 2nd quarter worth $4,260,000. Vanguard Group Inc. lifted its stake in shares of Catalyst Pharmaceuticals by 12.1% in the first quarter. Vanguard Group Inc. now owns 7,980,661 shares of the biopharmaceutical company’s stock valued at $127,212,000 after purchasing an additional 860,244 shares during the period. Finally, Allspring Global Investments Holdings LLC lifted its stake in shares of Catalyst Pharmaceuticals by 146.8% in the third quarter. Allspring Global Investments Holdings LLC now owns 366,444 shares of the biopharmaceutical company’s stock valued at $7,285,000 after purchasing an additional 217,956 shares during the period. Institutional investors and hedge funds own 79.22% of the company’s stock.

Wall Street Analyst Weigh In

CPRX has been the subject of several recent analyst reports. Citigroup raised their price objective on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the company a “buy” rating in a research note on Friday, August 9th. HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Friday, November 8th. Truist Financial raised their price objective on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, November 11th. Finally, StockNews.com upgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 9th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Catalyst Pharmaceuticals currently has an average rating of “Buy” and an average target price of $30.50.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other news, insider Steve Miller sold 150,000 shares of Catalyst Pharmaceuticals stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $20.35, for a total transaction of $3,052,500.00. Following the completion of the sale, the insider now directly owns 675,124 shares in the company, valued at $13,738,773.40. The trade was a 18.18 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director David S. Tierney sold 15,000 shares of Catalyst Pharmaceuticals stock in a transaction dated Wednesday, August 21st. The stock was sold at an average price of $20.10, for a total transaction of $301,500.00. Following the sale, the director now owns 348,874 shares of the company’s stock, valued at approximately $7,012,367.40. This trade represents a 4.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.00% of the stock is currently owned by insiders.

Catalyst Pharmaceuticals Trading Down 5.0 %

NASDAQ:CPRX opened at $20.60 on Friday. The firm has a 50-day moving average price of $20.99 and a two-hundred day moving average price of $18.32. Catalyst Pharmaceuticals, Inc. has a twelve month low of $13.00 and a twelve month high of $24.27. The company has a market capitalization of $2.46 billion, a P/E ratio of 17.46, a price-to-earnings-growth ratio of 3.51 and a beta of 0.75.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.